Replimune Group 株価情報 (NASDAQ: REPL)

最新ニュース Replimune Group (NASDAQ:REPL) 株価情報

Replimune Group

Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3.

Replimune Group Inc

REPLENISH NUTRIENTS HLDG by REPLENISH NUTRIENTS HLDG CORP.

Replenish Nutrients Holding Corp

REPLICEL LIFE SCIENCE ORD by RepliCel Life Sciences Inc.

RepliCel Life Sciences Inc

Repligen Corp

Reply SpA

News

General

TEAM

Williams Racing And Atlassian Enter Into Title Partnership To Form Atlassian Williams Racing

Wells Fargo analyst Joseph O'Dea maintains Rockwell Automation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ROK#NYSE">ROK</a>) with a Overweight and raises the price target from $315 to $337.

Price Target

Analyst Ratings

Wells Fargo Maintains Overweight on Rockwell Automation, Raises Price Target to $337

EON Resources Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EONR#NYSE">EONR</a>) ("EON" or the "Company") announced it has entered into an agreement with Pogo Royalty, LLC ("Pogo" or "Seller") that would result in a restructure of EON's balance sheet through (a) the retirement of a promissory note to Seller having an original principal amount of $15,000,000, (b) the purchase of a 10% Overriding Royalty Interest ("ORRI") in the Company's oil field property from Seller and (c) the repurchase of 100% of preferred units held by Seller in EON's subsidiary which would otherwise convert into the Company's Class A common stock on November 15, 2025 pursuant to a formula. The total consideration payable to Pogo in connection with the restructuring consists of $22,000,000 in cash from EON plus the issuance of 3,000,000 shares of the Company's Class A common stock to the Seller.
The agreement is subject to various closing conditions, including, without limitation, that the Company obtain adequate financing to fund the cash consideration portion, and that the agreement shall terminate if the closing does not take place within 120 days. The agreement also contains mutual general releases, which shall be effective upon the closing of the agreement.
The effect on the Company's balance sheet and financial position exclusive of the final financing arrangements the secure the $22 million in cash consideration is anticipated to include the following:
A reduction of liabilities comprised of principal and accrued interest debt owing to Seller of approximately $18,000,000
Reduction of $24,000,000 of redemption value of the currently outstanding preferred units held by Seller.
The ORRI which is valued at $14 million and is presently generating approximately $200,000 per month in proceeds.
The elimination of outstanding shares of the Company's Class B common stock.

EONR

EON Resources Moves to Restructure Balance Sheet With $22M Deal to Retire Debt and Reclaim Oil Royalties

Northland Capital Markets analyst Greg Gibas maintains PowerFleet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIOT#NASDAQ">AIOT</a>) with a Outperform and raises the price target from $10 to $11.

AIOT

Northland Capital Markets Maintains Outperform on PowerFleet, Raises Price Target to $11

Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) CEO Elon Musk said on Monday that the EV maker is &#8220;still on track&#8221; to launch <a href="https://www.benzinga.com/tech/25/01/43326143/tesla-stock-rises-5-after-hours-on-fsd-and-new-vehicle-promises-despite-q4-revenue-miss">autonomous ride-hailing in Austin, Texas</a> in June.
What Happened: Musk envisions deploying the company&#8217;s Model Y and Model 3 vehicles equipped with the company&#8217;s full self-driving driver assistance technology in Austin in June. While full self-driving currently requires active driver supervision, Musk and Tesla are optimistic that it can enable autonomous driving in time. 
&#8220;The threshold is achieving safety far in excess of the average human driver,&#8221; Musk said in a post on X.
The CEO on Monday also said that the company will roll out robotaxis to American cities beyond Austin before the end of the year. 
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">And it only gets better from here. Tesla is still on track to launch autonomous ride hailing in Austin in June and roll out to many cities in America by the end of this year. The threshold is achieving safety far in excess of the average human driver. Ultimately, autonomous… <a href="https://t.co/e81v28agSy">https://t.co/e81v28agSy</a>
&mdash; Harry Bōlz (@elonmusk) <a href="https://twitter.com/elonmusk/status/1889006561541882170?ref_src=twsrc%5Etfw">February 10, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
&#8220;Autonomy will make the stalk about as useful as an appendix,&#8221; Musk said in another post on X. 
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Autonomy will make the stalk about as useful as an appendix
&mdash; Harry Bōlz (@elonmusk) <a href="https://twitter.com/elonmusk/status/1889008569263046714?ref_src=twsrc%5Etfw">February 10, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Why It Matters: Tesla unveiled a<a href="https://www.benzinga.com/news/24/10/41284847/tesla-reveals-two-seater-cybercab-that-drives-itself"> Cybercab with no steering wheels or pedals</a> in October. The two-seat vehicle is meant for autonomous driving alone and is slated to start production in 2026 and join the company&#8217;s robotaxi fleet, which, until then, will be composed of the company&#8217;s Model 3 and Y vehicles.
Musk is currently banking big on autonomous driving to realize his vision for Tesla as an AI and robotics company and not merely a carmaker. 
Check out more of Benzinga&#8217;s Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43617724/deploying-tesla-superchargers-cost-40000-45000-per-stall-or-roughly-the-price-of-model-3-sedan-says-exec">Deploying Tesla Superchargers Cost $40,000-$45,000 Per Stall Or Roughly The Price Of Model 3 Sedan, Says Exec</a></li>
</ul>
Photo courtesy: Shutterstock

Tech

TSLA

Tesla 'Still On Track' To Launch Autonomous Ride Hailing In Austin By June, Says Elon Musk: '...It Only Gets Better From Here'

Entertainment

Sports

LTRY

Lottery.com's Brand Sports.com Inks Multi-Year Partnership Agreement With Soccerex

Wells Fargo analyst Larry Biegelsen maintains Inspire Medical Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INSP#NYSE">INSP</a>) with a Equal-Weight and lowers the price target from $198 to $195.

INSP

Wells Fargo Maintains Equal-Weight on Inspire Medical Systems, Lowers Price Target to $195

WIIM

AIFF

Firefly Neuroscience shares are trading higher after the company announced its acceptance into the NVIDIA Connect program.

NIO Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NIO#NYSE">NIO</a>) shares are trading lower in the premarket session on Tuesday despite a series of positive updates for the <a target="_blank" href="https://www.benzinga.com/premarket" rel="noreferrer noopener">electric vehicle maker.</a>
The company&#8217;s founder, chairman, and CEO, William Li, reportedly emphasized key strategic goals during an internal meeting as NIO prepares for 2025, <a target="_blank" href="https://cnevpost.com/2025/02/11/nio-ceo-highlights-importance-of-sales-volume-cost-reduction-in-internal-meeting/" rel="noreferrer noopener">reports </a>CnEV Post.
Li outlined three core visions for the company: doubling sales, achieving single-quarter profitability by the fourth quarter of 2025, and continuing to enhance systematic capabilities.
This meeting marked the company&#8217;s first quarterly gathering after celebrating its 10th anniversary.
Meanwhile, shares of other Chinese EV makers like XPeng Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPEV#NYSE">XPEV</a>) also fell on Tuesday.
The dip comes after Chinese EV giant&nbsp;BYD Co. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BYDDY#OTC">BYDDY</a>) launched smart driving features <a target="_blank" href="https://www.benzinga.com/tech/25/02/43617347/xpeng-geely-shares-fall-after-byd-launches-advanced-driver-assistance-features-on-car-priced-below-10000" rel="noreferrer noopener">on vehicles priced as low as&nbsp;$10,000.</a>
BYD on Monday rolled out an advanced driver-assist system called &#8220;God&#8217;s Eye&#8221; that it intends to install on a range of cars, including its low-cost Seagull hatchback priced under $10,000, for no added cost. The company began sales of 21 models equipped with the technology soon after the event.
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/25/02/43614807/byd-teams-up-with-deepseek-to-outpace-tesla-in-budget-friendly-ai-driven-tech-for-chinese-cars-amid-regulatory-roadblocks" rel="noreferrer noopener">BYD Teams Up With DeepSeek To Outpace Tesla In Budget-Friendly AI-Driven Tech For Chinese Cars Amid Regulatory Roadblocks</a>
Meanwhile, NIO&#8217;s performance during the <a target="_blank" href="https://www.benzinga.com/25/02/43560265/whats-going-on-with-nio-stock-today" rel="noreferrer noopener">Chinese New Year holiday also stands out.</a> The company saw a surge in demand for its battery swap services, with 136,720 services recorded on February 3 alone.
This marked a peak in demand following a strong performance on January 25, with 119,848 services in a single day.
Additionally, NIO reported a 37.9% year-over-year increase in vehicle deliveries for January 2025, reaching 13,863 units.
Adding to the optimism, NIO is expected to be included in a major Hong Kong stock index after the Hang Seng Indexes Company Limited&#8217;s semi-annual review on February 21. This potential inclusion could attract passive investment inflows, providing a boost to the company&#8217;s stock price when the changes take effect on March 10.
Price Action: NIO shares are trading lower by 2.19% to $4.235 premarket at last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/25/02/43608052/traders-rethink-interest-rate-path-as-inflation-concerns-resume-feds-rate-cutting-cycle-is-over-economist-says" target="_blank" rel="noreferrer noopener">Traders Rethink Interest-Rate Path As Inflation Concerns Resume: &#8216;Fed&#8217;s Rate-Cutting Cycle Is Over,&#8217; Economist Says</a></li>
</ul>
Photo by Sundry Photography on Shutterstock.

Equities

Markets

Movers

Media

BYDDY

XPEV

What's Going On With Chinese EV Maker NIO Stock On Tuesday?

Silo Pharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SILO#NASDAQ">SILO</a>) ("Silo" or the "Company"), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced a positive update from an ongoing study evaluating the pharmacokinetics, safety and tolerability of its novel SP-26 ketamine extended-release rods when implanted subcutaneously. The SP-26 implant is a novel self-administered, non-opioid therapeutic intended for the treatment of chronic pain and fibromyalgia.
The launch of our non-GLP study in December 2024 marked the first small animal testing of SP-26, a key preclinical milestone. Implantation (dosing) was completed in the first week of January 2025 and no animals experienced serious side effects or discomfort. Absorption, distribution, metabolism, and excretion (ADME) testing is nearing completion and final safety, and pharmacokinetic reports are expected in March 2025.

SILO

Silo Pharma's SP-26 Implant Shows Early Results in Chronic Pain and Fibromyalgia Study

Wells Fargo analyst Michael Berg maintains Monday.Com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNDY#NASDAQ">MNDY</a>) with a Overweight and raises the price target from $340 to $380.

MNDY

Wells Fargo Maintains Overweight on Monday.Com, Raises Price Target to $380

NVDA

Firefly Neuroscience Gains Acceptance Into NVIDIA Connect Program

Insurance

SPNS

Sapiens Launches Sapiens UnderwritingPro v14 Underwriting Solution For Life & Annuities Insurers

Wells Fargo analyst Chris Carey maintains Edgewell Personal Care (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EPC#NYSE">EPC</a>) with a Overweight and lowers the price target from $37 to $35.

Wells Fargo Maintains Overweight on Edgewell Personal Care, Lowers Price Target to $35

On Monday, Rocket Lab USA, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NASDAQ">RKLB</a>) disclosed that it will launch a satellite for BlackSky Technology Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BKSY#NYSE">BKSY</a>) on a dedicated Electron mission, the first of multiple planned launches under a bulk order with <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/b43609169/rocket-lab-schedules-launch-for-first-of-multiple-missions-for-blacksky" rel="noreferrer noopener">the space-based intelligence company</a>.
The &#8220;Fasten Your Space Belts&#8221; mission will launch from Rocket Lab Launch Complex 1 in New Zealand, with a launch window opening on February 18 UTC.
The company will deploy BlackSky's first Gen-3 Earth-imaging satellite into a 470km circular orbit.
This marks Rocket Lab's ninth launch for BlackSky since 2019. The mission will bring Rocket Lab&#8217;s total deployed satellites to 210 and followed a record 16 successful launches in 2024.
Each BlackSky mission includes a Rocket Lab Motorized Lightband separation system, showcasing the company&#8217;s vertical integration and capability to deliver launch, satellite, and spacecraft component solutions.
&#8220;Fasten Your Space Belts&#8221; marks Rocket Lab&#8217;s second mission of 2025 and its 60th Electron launch. The 2025 manifest includes Electron missions for commercial and government customers, along with HASTE missions from Launch Complex 2, with launch windows to be announced later.
Rocket Lab founder and CEO, Sir Peter Beck said, &#8220;Electron is a trusted and reliable constellation builder for companies like BlackSky, allowing them to be in control of how, when, and where to deploy their constellation.&#8221;
&#8221;BlackSky is one of our earliest and longest-standing commercial satellite customers, and it&#8217;s great to be heading back to the pad with them once again to continue to advance and expand their constellation.&#8221;
Also, over the weekend, the company successfully&nbsp;completed its 59th Electron mission. The mission saw the deployment of five satellites into Low Earth Orbit for&nbsp;Kinéis, <a target="_blank" href="https://www.benzinga.com/25/02/43602341/rocket-labs-iot-constellation-for-kineis-takes-off" rel="noreferrer noopener">a French Internet-of-Things operator</a>.
Investors can gain exposure to the stock via&nbsp;ARK Space Exploration &amp; Innovation ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKX#BATS">ARKX</a>) and Procure Space ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UFO#NASDAQ">UFO</a>).
Price Action: RKLB shares are trading lower by 1.96% at $30.00 premarket at the last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/25/02/43577796/cathie-woods-ark-invest-bets-big-on-amazon-roblox-and-illumina-while-trimming-palantir-stake-after-alex-karp-led-company-touched-an-all-time-high-on-thursday" target="_blank" rel="noreferrer noopener">Cathie Wood&#8217;s Ark Invest Bets Big On Amazon, Roblox And Illumina While Trimming Palantir Stake After Alex Karp-Led Company Touched An All-Time High On Thursday</a></li>
</ul>

Large Cap

Contracts

ARKX

BlackSky Technology Inc. Class A Common Stock

BKSY

RKLB

Rocket Lab Gears Up For BlackSky's Gen-3 Satellite Launch: Details

Morgan Stanley analyst Joseph Moore maintains ON Semiconductor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ON#NASDAQ">ON</a>) with a Underweight and lowers the price target from $52 to $44.

Morgan Stanley Maintains Underweight on ON Semiconductor, Lowers Price Target to $44

Wells Fargo analyst Jason Haas maintains FactSet Research Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDS#NYSE">FDS</a>) with a Equal-Weight and lowers the price target from $503 to $500.

Wells Fargo Maintains Equal-Weight on FactSet Research Systems, Lowers Price Target to $500

ESSA Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EPIX#NASDAQ">EPIX</a>) reported quarterly losses of $(0.19) per share which missed the analyst consensus estimate of $(0.12) by 58.33 percent. This is a 35.71 percent decrease over losses of $(0.14) per share from the same period last year.

Earnings

Earnings Misses

EPIX

ESSA Pharma Q1 2025 GAAP EPS $(0.19) Misses $(0.12) Estimate, Cash $120.6M

Morgan Stanley analyst Kallum Titchmarsh maintains Inspire Medical Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INSP#NYSE">INSP</a>) with a Overweight and lowers the price target from $230 to $220.

Morgan Stanley Maintains Overweight on Inspire Medical Systems, Lowers Price Target to $220

Health Care

CRBP

Corbus Pharmaceuticals To Present Clinical Data For CRB-701 From Western Dose Escalation Study 2025 ASCO-GU

Analyst Song holds a group dinner meeting in New York on December 17 at 6 pm hosted by Jefferies. Published first on TheFly – the ultimate source f...

Replimune management to meet with Jefferies

Replimune (REPL) Group announced that the first patients have been enrolled in studies evaluating RP2 in two different settings: checkpoint naive m...

Replimune announces RP2 development program advances

Evan Seigerman, an analyst from BMO Capital, has initiated a new Buy rating on Replimune Group (REPL). Evan Seigerman has given his Buy rating due ...

Replimune Group's Strategic Advances Highlight Promising Potential in Oncolytic Virus Therapy

In a report released today, Peter Lawson from Barclays maintained a Buy rating on Replimune Group (REPL – Research Report), with a price target of ...

Replimune Group (REPL) Receives a Buy from Barclays

Replimune announces priority review for its melanoma treatment

Biggest stock movers Tuesday: RDW, CAN, EOLS, REPL, EDU, FTAI and more

H.C. Wainwright analyst Robert Burns raised the firm's price target on Replimune (REPL) to $21 from $17 and keeps a Buy rating on the shares. The f...

Replimune price target raised to $21 from $17 at H.C. Wainwright

BMO Capital analyst Evan Seigerman raised the firm's price target on Replimune (REPL) to $27 from $18 and keeps an Outperform rating on the shares....

Replimune price target raised to $27 from $18 at BMO Capital

Leerink Partners analyst Jonathan Chang has reiterated their bullish stance on REPL stock, giving a Buy rating yesterday. Jonathan Chang has given ...

Replimune Group's Promising Outlook: FDA Priority Review and Positive Trial Data Support Buy Rating

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Replimune Group (REPL – Research Report), Pliant The...

Analysts Offer Insights on Healthcare Companies: Replimune Group (REPL), Pliant Therapeutics (PLRX) and Immunovant (IMVT)

EOLS

FTAI

IMVT

NWOEF

PLRX

REPL

VATE

Press Releases

Replimune Presents Late-Breaking Abstract Featuring Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-PD1 Failed Melanoma at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2024)

Replimune Reports Fiscal Second Quarter 2025 Financial Results and Provides Corporate Update

Replimune Receives Breakthrough Therapy Designation for RP1 and Submits RP1 Biologics License Application to the FDA under the Accelerated Approval Pathway

Replimune Announces Proposed Public Offering

Replimune Announces Pricing of Upsized Public Offering

Replimune to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Replimune Announces RP2 Development Program Advances with First Patients Enrolled in Metastatic Uveal Melanoma and Hepatocellular Carcinoma Clinical Trials

Comments

Replimune Group

ニュース

最新ニュース Replimune Group (NASDAQ:REPL) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル